Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04KJO
|
||||
| Former ID |
DAP000247
|
||||
| Drug Name |
Formoterol
|
||||
| Synonyms |
Arformoterol; Eformoterol; Foradil; Foradile; Formoterolum; Oxis; FORMOTEROL FUMARATE; Formoterol tartrate; Oxeze Turbuhaler; Oxeze Turbuhaler Foradil; MOLI000351; Arformoterol (INN); Atimos (TN); Atock (TN); Foradil (TN); Foradile (TN); Formoterol (INN); Formoterolum [INN-Latin]; Modulite (TN); Oxeze (TN); Oxis (TN); Perforomist (TN); Formoterol [USAN:INN:BAN]; Formoterol, ((R*,R*)-(+-)-)-isomer; N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide; N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; N-[2-hydroxy-5-[(1S)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide; N-{2-hydroxy-5-[(1R)-1-hydroxy-2-({(1R)-1-methyl-2-[4-(methyloxy)phenyl]ethyl}amino)ethyl]phenyl}formamide; (+-)-2'-Hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide; (-)-Formoterol; (R,R)-Formoterol; 3-formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Sympathomimetics
|
||||
| Company |
Norvatis Phamaceuticals Corporation
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H24N2O4
|
||||
| InChI |
InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)
|
||||
| InChIKey |
BPZSYCZIITTYBL-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 73573-87-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
10007, 5643479, 8152174, 14875897, 29222544, 46507099, 50125837, 50940891, 53790377, 57321784, 85209082, 92712339, 96024684, 103837996, 104303431, 117625425, 125564207, 126625648, 126656778, 126670908, 127551521, 134337561, 135610485, 136352502, 137070085, 142452394, 144224272, 152100598, 160964320, 162178864, 163329494, 176251370, 178100459, 179148573, 196111556, 198992021, 206246320, 221672992, 223400949, 223680169, 223781951, 226683973, 240785438
|
||||
| SuperDrug ATC ID |
R03AC13
|
||||
| SuperDrug CAS ID |
cas=043229807
|
||||
| Target and Pathway | |||||
| Target(s) | Beta-2 adrenergic receptor | Target Info | Agonist | [534986], [535115], [535518] | |
| NetPath Pathway | TCR Signaling Pathway | ||||
| Pathway Interaction Database | Arf6 trafficking events | ||||
| Arf6 signaling events | |||||
| References | |||||
| Ref 536535 | Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients. Respir Med. 2008 Mar;102(3):449-56. Epub 2007 Nov 19. | ||||
| Ref 540403 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3465). | ||||
| Ref 534986 | Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2000;(2):CD001104. | ||||
| Ref 535115 | Tocolytic effects of a long-acting beta2-adrenoceptor agonist, formoterol, in rats. J Pharm Pharmacol. 2000 Nov;52(11):1417-23. | ||||
| Ref 535518 | Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.